

New OEB5 R&D Facility Establishes Comprehensive High-Potency Drug Platform

Asymchem has successfully completed construction of a new state-of-the-art OEB5 R&D facility this month, with operations set to launch shortly. Spanning 3,200 m² across four floors, the new facility complements our existing OEB5 site to form a fully integrated R&D, Manufacturing & Analytics service platform. This expansion enables standardized, fully enclosed operations tailored to high-potency drug development.

Accelerated Re-Commissioning of the Sandwich Pilot Plant for GMP Production

Asymchem successfully re-commissioned the Sandwich Pilot Plant for GMP manufacturing within five months of acquisition. Designed for small molecule clinical API production, the facility operates at default OEB4 containment, with upgrade options to OEB5. It supports flexible batch sizes from 2 kg to 150 kg, housing 24 reactor vessels with a total capacity of 23 m³ and is equipped for hydrogenation, cryogenic chemistry, and biocatalytic processes, with all operations managed through an advanced DCS system. A computerized maintenance management system (CMMS) and electronic inventory system further enhance efficiency in cGMP operations.

Key Features of the New Facility Include:

- A highly experienced, specialized R&D team
 - Rigorous safety standards with OEL ≤0.001 μg/m³
 - Full sterility and limit testing capabilities
 - Industry-leading containment technologies, including Grade A negative pressure isolators, microbal-ance-compatible isolators, and VBE systems.
 - Comprehensive physicochemical analytical capabilities: HPLC, GC, HS-GC, KF, pH, IR, KF-C, Polarimeter, EC meter, etc.

By leveraging deep expertise,
Asymchem's new OEB5 R&D facility
greatly strengthens its capabilities in
high-potency API development. We
remain committed to delivering
end-to-end solutions for our global
partners.



Recent manufacturing campaigns have demonstrated the strengths of both the facility and technical teams:

- 4-week turnaround from purchase order to manufacturing launch
- Flexible operations that maximize process understanding and data collection
- Real-time collaboration with clients during plant operations
- Rapid, scalable process optimization without timeline delays
- On average, a 10% yield improvement and higher-than-expected product purity

ExpandingOur Capabilities

We are excited to announce that our Kilo-lab at the Boston site is now fully operational. The facility is designed to fully support cGMP manufacturing for small-molecule RSMs, intermediates, and APIs. These capabilities enable process development and production at kilogram scales, allowing us to better meet increasing project demands.

Contact us to learn how mehem Boston can support your small molecule API development needs today!

USA Woburn, MA